Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
D.Western Therapeutics Institute, Inc. ( (JP:4576) ) has issued an update.
D. Western Therapeutics Institute, Inc. announced the FDA’s acceptance of their New Drug Application for DW-5LBT, a lidocaine patch for post-herpetic neuralgia. This acceptance marks the beginning of a full-scale review, with a target action date set for September 24, 2025. While this development will not affect the company’s fiscal forecast for the year ending December 2025, it is anticipated to enhance earnings in the medium to long term, potentially positioning DW-5LBT as a superior alternative in the lidocaine patch market.
More about D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. operates in the pharmaceutical industry, focusing on the development of therapeutic products. The company is involved in the co-development of a novel lidocaine patch, DW-5LBT, designed to treat post-herpetic neuralgia, in collaboration with MEDRx, Co., Ltd.
YTD Price Performance: -50.0%
Technical Sentiment Signal: Strong Buy
Current Market Cap: €29.66M
For detailed information about 4576 stock, go to TipRanks’ Stock Analysis page.